{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T05:06:02Z","timestamp":1775279162522,"version":"3.50.1"},"reference-count":21,"publisher":"Japanese Society of Toxicology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Toxicol. Sci."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2131\/jts.51.251","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T22:14:02Z","timestamp":1774995242000},"page":"251-258","source":"Crossref","is-referenced-by-count":0,"title":["Considerations for infection risks identified in target safety review"],"prefix":"10.2131","volume":"51","author":[{"given":"Yuichiro","family":"Amano","sequence":"first","affiliation":[{"name":"Nonclinical Safety and Pharmacology, Research, Takeda Pharmaceutical Company Limited"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Inui","sequence":"additional","affiliation":[{"name":"Nonclinical Safety and Pharmacology, Research, Takeda Pharmaceutical Company Limited"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Nonclinical Safety and Pharmacology, Research, Takeda Pharmaceutical Company Limited"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jodi","family":"Goodwin","sequence":"additional","affiliation":[{"name":"Nonclinical Safety and Pharmacology, Research, Takeda Pharmaceutical Company Limited"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"898","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Adas, M.A., Alveyn, E., Cook, E., Dey, M., Galloway, J.B. and Bechman, K. (2022): The infection risks of JAK inhibition. Expert Rev. Clin. Immunol., <b>18<\/b>, 253-261.","DOI":"10.1080\/1744666X.2022.2014323"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Ahmed, N., Oluwole, O., Mahmoudjafari, Z., Suleman, N. and McGuirk, J.P. (2024): Managing Infection Complications in the Setting of Chimeric Antigen Receptor T cell (CAR-T) Therapy. Clin. Hematol. Int., <b>6<\/b>, 31-45.","DOI":"10.46989\/001c.115932"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Amano, Y., Jeffy, B., Anayama, H. and Goodwin, J. (2025): Incorporation of target safety review in drug discovery. J. Toxicol. Sci., <b>50<\/b>, 593-599.","DOI":"10.2131\/jts.50.593"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Bahr, N.C., Benedict, K., Toda, M., Gold, J.A. and Lipner, S.R. (2024): Low incidence of invasive fungal infections in a large observational cohort of patients initiating IL-17 or IL-23 inhibitor therapy, United States, 2016-2022. J. Am. Acad. Dermatol., <b>91<\/b>, 119-122.","DOI":"10.1016\/j.jaad.2024.02.045"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Blauvelt, A., Chiricozzi, A., Ehst, B.D. and Lebwohl, M.G. (2023): Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review. Adv. Ther., <b>40<\/b>, 3410-3433.","DOI":"10.1007\/s12325-023-02568-0"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Brennan, R.J. (2017): Target Safety Assessment: strategies and Resources. Methods Mol. Biol., <b>1641<\/b>, 213-228.","DOI":"10.1007\/978-1-4939-7172-5_12"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Bulitta, J.B., Hope, W.W., Eakin, A.E., Guina, T., Tam, V.H., Louie, A., Drusano, G.L. and Hoover, J.L. (2019): Generating Robust and Informative Nonclinical <i>In Vitro<\/i> and <i>In Vivo<\/i> Bacterial Infection Model Efficacy Data To Support Translation to Humans. Antimicrob. Agents Chemother., <b>63<\/b>, e02307-e02318.","DOI":"10.1128\/AAC.02307-18"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Demirbas, A., Diremsizoglu, E., Esen, M. and Ulutas Demirbas, G. (2025): Unveiling the effectiveness and safety spectrum of biologic therapies in psoriasis: a three-year real-world analysis. Postgrad. Med., <b>137<\/b>, 299-308.","DOI":"10.1080\/00325481.2025.2493042"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Friberg, L.E. (2021): Pivotal Role of Translation in Anti-Infective Development. Clin. Pharmacol. Ther., <b>109<\/b>, 856-866.","DOI":"10.1002\/cpt.2182"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Goodstal, S.M., Lin, J., Crandall, T., Crowley, L., Bender, A.T., Pereira, A., Soloviev, M., Wesolowski, J.S., Iadevaia, R., Schelhorn, S.E., Ross, E., Morandi, F., Ma, J. and Clark, A. (2023): Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies. Sci. Rep., <b>13<\/b>, 20412.","DOI":"10.1038\/s41598-023-47735-z"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Kong, L.Z., Kim, S.M., Wang, C., Lee, S.Y., Oh, S.C., Lee, S., Jo, S. and Kim, T.D. (2023): Understanding nucleic acid sensing and its therapeutic applications. Exp. Mol. Med., <b>55<\/b>, 2320-2331.","DOI":"10.1038\/s12276-023-01118-6"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Mestas, J. and Hughes, C.C. (2004): Of mice and not men: differences between mouse and human immunology. J. Immunol., <b>172<\/b>, 2731-2738.","DOI":"10.4049\/jimmunol.172.5.2731"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Netea, M.G., Balkwill, F., Chonchol, M., Cominelli, F., Donath, M.Y., Giamarellos-Bourboulis, E.J., Golenbock, D., Gresnigt, M.S., Heneka, M.T., Hoffman, H.M., Hotchkiss, R., Joosten, L.A., Kastner, D.L., Korte, M., Latz, E., Libby, P., Mandrup-Poulsen, T., Mantovani, A., Mills, K.H., Nowak, K.L., O\u2019Neill, L.A., Pickkers, P., van der Poll, T., Ridker, P.M., Schalkwijk, J., Schwartz, D.A., Siegmund, B., Steer, C.J., Tilg, H., van der Meer, J.W., van de Veerdonk, F.L. and Dinarello, C.A. (2017): A guiding map for inflammation. Nat. Immunol., <b>18<\/b>, 826-831.","DOI":"10.1038\/ni.3790"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Newburger, P.E. and Dale, D.C. (2013): Evaluation and management of patients with isolated neutropenia. Semin. Hematol., <b>50<\/b>, 198-206.","DOI":"10.1053\/j.seminhematol.2013.06.010"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Pognan, F., Beilmann, M., Boonen, H.C., Czich, A., Dear, G., Hewitt, P., Mow, T., Oinonen, T., Roth, A., Steger-Hartmann, T., Valentin, J.P., Van Goethem, F., Weaver, R.J. and Newham, P. (2023): The evolving role of investigative toxicology in the pharmaceutical industry. Nat. Rev. Drug Discov., <b>22<\/b>, 317-335.","DOI":"10.1038\/s41573-022-00633-x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Rubic-Schneider, T., Christen, B., Brees, D. and Kamm\u00fcller, M. (2016): Minipigs in Translational Immunosafety Sciences: A Perspective. Toxicol. Pathol., <b>44<\/b>, 315-324.","DOI":"10.1177\/0192623315621628"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Sarkar, S. and Heise, M.T. (2019): Mouse Models as Resources for Studying Infectious Diseases. Clin. Ther., <b>41<\/b>, 1912-1922.","DOI":"10.1016\/j.clinthera.2019.08.010"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Tamaki, C., Nagayama, T., Hashiba, M., Fujiyoshi, M., Hizue, M., Kodaira, H., Nishida, M., Suzuki, K., Takashima, Y., Ogino, Y., Yasugi, D., Yoneta, Y., Hisada, S., Ohkura, T. and Nakamura, K. (2013): Potentials and limitations of nonclinical safety assessment for predicting clinical adverse drug reactions: correlation analysis of 142 approved drugs in Japan. J. Toxicol. Sci., <b>38<\/b>, 581-598.","DOI":"10.2131\/jts.38.581"},{"key":"19","doi-asserted-by":"crossref","unstructured":"T\u00e4ngd\u00e9n, T., Lundberg, C.V., Friberg, L.E. and Huttner, A. (2020): How preclinical infection models help define antibiotic doses in the clinic. Int. J. Antimicrob. Agents, <b>56<\/b>, 106008.","DOI":"10.1016\/j.ijantimicag.2020.106008"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Youssef, J., Novosad, S.A. and Winthrop, K.L. (2016): Infection Risk and Safety of Corticosteroid Use. Rheum. Dis. Clin. North Am., <b>42<\/b>, 157-176. ix-x.","DOI":"10.1016\/j.rdc.2015.08.004"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Xu, Q. and Huang, L. (2023): B cell depletion therapies in autoimmune diseases: monoclonal antibodies or chimeric antigen receptor-based therapy? Front. Immunol., <b>14<\/b>, 1126421.","DOI":"10.3389\/fimmu.2023.1126421"}],"container-title":["The Journal of Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/51\/4\/51_251\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T04:23:51Z","timestamp":1775276631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/51\/4\/51_251\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2131\/jts.51.251","relation":{},"ISSN":["0388-1350","1880-3989"],"issn-type":[{"value":"0388-1350","type":"print"},{"value":"1880-3989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}